SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple's earnings are driving a lot of chatter, with the community dissecting the details and debating future performance. While some are concerned about decreased sales in China, others are optimistic due to strong iPhone demand and raised price targets from analysts. The conversation centers around whether Apple can maintain its rally and justify its valuation.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending amid discussions around strong earnings and future outlook, with revenue exceeding expectations. The community is focused on a potential short squeeze and the impact of AI-driven advertising, while some express concern over user growth and platform moderation policies. Bullish sentiment is countered by those anticipating an overnight tank, making for a volatile discussion.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as the community discusses recent price volatility and a rejected acquisition offer, with some speculating about market manipulation and short squeezes. Despite positive catalysts like increased revenue guidance and progress in Montana mining operations, the stock's performance has sparked debate about its true value and potential government support. Discussions also involve the broader antimony sector and its strategic importance amid global trade dynamics.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to investor reactions to earnings, with concerns around increased AI spending and a substantial one-time tax charge overshadowing otherwise positive results. Community discussions focus on whether the dip presents a buying opportunity or signals deeper issues with Meta's long-term strategy, particularly its AI investments. Bond investors are showing confidence, but the stock market's initial reaction has been negative.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending due to positive community sentiment following Q3 earnings, which highlighted strong Ibsrela revenue growth and pipeline expansion, despite some challenges with Xphozah's Medicare coverage. Discussions center on the company's growth trajectory, potential profitability, and analyst price targets, with some investors anticipating further gains; however, others remain cautious due to past volatility and risks around cash flow.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending amid heated debates over its legitimacy, with some community members alleging fraudulent activity and liquidity removal by the founder, while others defend the project, citing its partnerships and venture backing. Discussions also revolve around its potential integration with major payment systems and the upcoming release of a 'Super App,' with some expressing optimism and others warning of a 'pump and dump' scheme.

UP AND TO THE RIGHT

UPRIGHT CRYPTO is gaining attention for its constructive chart patterns, with many community members noting the potential for a breakout. Discussions highlight the steady accumulation and consistent higher lows, suggesting a solid foundation. The community buzz indicates growing confidence and anticipation for a significant move.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

Solid Power is trending due to positive sentiment around its solid-state battery technology, particularly following news of a joint evaluation agreement with Samsung SDI and BMW. Community members are highlighting the potential for Solid Power's batteries in various sectors beyond EVs, including energy storage and aviation, while also noting the company's position as a U.S.-based entity amid concerns around reliance on China for battery technology and materials.

DLH Holdings Corp. engages in the provision of technology enabled business process outsourcing program management solutions and public health research and analytics. Its services and solutions include Defense and Veteran Health Solutions, Human Services and Solutions, Public Health and Life Sciences, and Infinibyte Cloud. The company was founded in 1969 and is headquartered in Atlanta, GA.

DLH Holdings Corp

DLHC is trending due to a recently secured $90M contract with Veteran Affairs, sparking considerable excitement within the community. Discussions revolve around the company's low float, positive net income, and potential for substantial growth, with some anticipating a significant price surge. The contract win is seen as a major catalyst, reinforcing the company's growth prospects in the government services sector.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy Inc. ($MSTR) is trending as investors discuss its recent earnings report and its correlation with Bitcoin's price movements, with some anticipating inclusion in the S&P 500. Community discussions revolve around whether $MSTR is overvalued and potential short squeezes, while others remain skeptical of its long-term strategy amidst Bitcoin's volatility. Many are closely watching key price levels and options activity, anticipating a significant move following the earnings release.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Equity

Global X Funds - Global X Guru Index ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

GURU
Global X Funds - Global X Guru Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GURU News

GURUGlobal X Funds - Global X Guru Index ETF